𝗦𝘁𝗿𝗼𝗻𝗴 𝗻𝗲𝘄𝘀 𝗳𝗿𝗼𝗺 𝗼𝘂𝗿 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀: The new clinical data on daraxonrasib show great potential to significantly improve the treatment of pancreatic cancer. An important step towards new and urgently needed therapies for this hard-to-treat disease. ⬇️

New Targeted Therapy for HER2-Mutant NSCLC Gains FDA Approval & NCCN Guideline Inclusion A new milestone in lung cancer treatment: the FDA has granted accelerated approval to Hernexeos (zongertinib), an oral kinase inhibitor for adults with advanced HER2-mutant non-squamous NSCLC who have received prior systemic therapy. Zongertinib offers a chemotherapy-free targeted approach, addressing a long-standing unmet need. Shortly after approval, it was incorporated as a preferred therapy in the NCCN Guidelines (NSCLC v8.2025), reinforcing its role in clinical practice. While further data are required to confirm long-term benefit, this represents a significant advancement in personalized cancer therapy—underscoring the importance of molecular testing and continuous updates to clinical guidelines. #Oncology #LungCancer #NSCLC #HER2 #TargetedTherapy #CancerTreatment #PrecisionMedicine #Pharma #DrugDevelopment #FDAApproval #NCCNGuidelines

Limited BCG supply is forcing clinicians to rethink how they manage intermediate-risk bladder cancer. Dr. Amy Luckenbaugh reviews alternatives to BCG in intermediate-risk disease, such as gemcitabine and hydrogel-based mitomycin. She also discusses emerging agents - many positioned as salvage therapies post-BCG - and notes the impact of cost in this evolving treatment landscape. Watch the full episode here: https://lnkd.in/eRXrhS4U This campaign is supported by an educational grant from UroGen Pharma. UGN-102 was approved by the FDA on June 12, 2025. #URO253 #bladdercancer #BCG #intravesicaltherapy #oncology #intermediaterisk

CARES-310 Final Analysis: Camrelizumab + Rivoceranib vs Sorafenib in uHCC In July 2025, Richard Kim and colleagues presented the final analysis of the CARES-310 trial, confirming the significant survival benefit of camrelizumab + rivoceranib over sorafenib in unresectable hepatocellular carcinoma (uHCC). Median overall survival reached 23.8 months vs 15.2 months with sorafenib (HR 0.64, p<0.0001), and progression-free survival was 5.6 vs 3.7 months (HR 0.54, p<0.0001). Importantly, benefit was observed regardless of baseline AFP level or HBV etiology, with consistent improvements in both low (<400 ng/mL) and high (≥400 ng/mL) AFP subgroups. Kudos to Richard Kim and the CARES-310 investigators for advancing first-line therapy options in uHCC and providing valuable insights into biomarker-based outcomes. Read more: https://lnkd.in/d2sq73zb #HCC #LiverCancer #Immunotherapy #Camrelizumab #Rivoceranib #ESMO2025 #ClinicalResearch #Oncology

🚨 Biopharma Update On Sept 23, Hengrui announced that the NMPA has accepted the NDA for a new indication of adebelimab injection. 🔹 Treatment plan: platinum-based chemotherapy as neoadjuvant therapy, followed by adebelimab monotherapy as adjuvant therapy 🔹 Target patients: resectable stage II, IIIA, and IIIB NSCLC without EGFR mutations or ALK rearrangements Another important step in advancing lung cancer treatment in China. What are your thoughts on the impact of this potential new option for NSCLC patients? 💬 #Biopharma #Oncology #LungCancer #NSCLC #Immunotherapy #DrugDevelopment

CisGem + Pembrolizumab in Advanced BTC: Phase II Results from EORTC 1607-GITCG/ABC-09 | ESMO 2025 At ESMO 2025, Markus Moehler and colleagues presented results from a multi-center, single-arm phase II trial investigating first-line cisplatin/gemcitabine plus pembrolizumab (CisGem-pembro) in advanced biliary tract cancer. Among 50 enrolled patients, the combination achieved an objective response rate of over 40%, median progression-free survival exceeding 8 months, and a median overall survival of 13.4 months. Grade 3–4 toxicities were manageable and consistent with known profiles. Notably, patients with higher CPS scores demonstrated improved outcomes, supporting the relevance of biomarker-driven approaches. Congratulations to Markus Moehler and the EORTC-1607-GITCG/ABC-09 team for delivering robust data that may inform future biomarker-guided strategies in BTC. Read more:https://lnkd.in/dUhfKqfR #ESMO2025 #BiliaryTractCancer #Cholangiocarcinoma #GallbladderCancer #Immunotherapy #Pembrolizumab #CisGem #Oncology #TranslationalResearch #OncologyFrontier

Roche’s oral SERD achieves Phase III success 📢 On Sept 22, Roche announced positive results from the evERA Phase III trial. This randomized, open-label, multi-center study evaluated Giredestrant + Everolimus vs. standard endocrine therapy + Everolimus in HR+ / HER2- locally advanced or metastatic breast cancer patients previously treated with CDK4/6 inhibitors and endocrine therapy. ✨ Importantly, this is the first head-to-head Phase III trial to show positive outcomes for an all-oral SERD regimen combined with standard treatment. 🔑 Co-primary endpoint: Investigator-assessed Progression-Free Survival (PFS) in both the ITT population and ESR1 mutation subgroup. 📌 Key secondary endpoints: Overall Survival (OS), Objective Response Rate (ORR), Duration of Response (DoR), Clinical Benefit Rate, and safety. #Roche #BreastCancer #SERD #Oncology #ClinicalTrials #DrugDevelopment #Biopharma #TargetedTherapies #CancerResearch #PrecisionOncology #EndocrineTherapy #MetastaticBreastCancer #PharmaInnovation #LifeSciences #DrugDiscovery

🚨 FDA Approval Alert ! ✅ Roche’s Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with Zepzelca® (lurbinectedin) approved as the first-line maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC). 📊 In the Phase III IMforte study, the combo reduced the risk of disease progression or death by 46% and the risk of death by 27%. 🔗 Read more: bit.ly/ONCOnews3O-1 #ONCOnews #OncoAlert #OncEd #LungCancer #SCLC #FDAApproval #CancerTreatment

This post is intended for a US audience.      Today, AstraZeneca and our partners at Daiichi Sankyo announced the US FDA granted Priority Review for our HER2-directed antibody-drug conjugate (ADC) in combination with another therapy for the treatment of 1st-line HER2-positive metastatic breast cancer (mBC), based on results from the DESTINY-Breast09 Phase III trial.     HER2-positive mBC is an aggressive disease with a poor prognosis, with most patients experiencing progression within two years of 1st-line treatment. We’re aiming to bring a new treatment option into the 1st-line setting for HER2-positive mBC, where the current standard of care has been in place for more than a decade.     Learn more about what this milestone could mean for patients: https://lnkd.in/epXPDziw #USOnly #AstraZenecaUS